AKT1 and Cognitive impairment: Pharmacological interventions revealed that the PI3K‐AKT inhibitor LY294002 (0.8 μM in 0.5 μL) but not IGFR1 antagonist JB‐1 (0.8 μM in 0.5 μL) completely abolished WNT3a‐mediated improvements in neuropathic pain behaviors and cognitive impairment in SNI mice (Figure 9I–K).